Truist Securities Maintains Buy on Pacira BioSciences, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Truist Securities maintains a Buy rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $45 to $30.

July 25, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Pacira BioSciences but lowers the price target from $45 to $30.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100